[go: up one dir, main page]

MX2015011350A - Proteinas de fusion de apelina y usos de estas. - Google Patents

Proteinas de fusion de apelina y usos de estas.

Info

Publication number
MX2015011350A
MX2015011350A MX2015011350A MX2015011350A MX2015011350A MX 2015011350 A MX2015011350 A MX 2015011350A MX 2015011350 A MX2015011350 A MX 2015011350A MX 2015011350 A MX2015011350 A MX 2015011350A MX 2015011350 A MX2015011350 A MX 2015011350A
Authority
MX
Mexico
Prior art keywords
apelin
domain
fusion polypeptides
fusion proteins
aplnr
Prior art date
Application number
MX2015011350A
Other languages
English (en)
Other versions
MX365551B (es
Inventor
Stevis Panayiotis
Jesper Gromada
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2015011350A publication Critical patent/MX2015011350A/es
Publication of MX365551B publication Critical patent/MX365551B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un polipéptido o proteína de fusión que comprende un péptido apelina fusionado a un componente de multimerización. La invención también proporciona un polipéptido o proteína de fusión que comprende un péptido apelina fusionado a un dominio Fc, un fragmento de un dominio Fc o una variante de un dominio Fc. Los polipéptidos de fusión Apelina Fc son capaces de unirse al receptor de apelina (APLNR). Los polipéptidos de fusión a apelina Fc pueden activar la APLNR y presentan mejores propiedades farmacocinéticas en comparación con los péptidos apelina que no se fusionan con un Fc o fragmento de Fc. Los polipéptidos de fusión a apelina Fc son útiles en enfermedades y afecciones relacionadas con la función cardiovascular, diabetes, cáncer, obesidad y otras afecciones relacionadas con apelina.
MX2015011350A 2013-03-14 2014-03-14 Proteinas de fusion de apelina y usos de estas. MX365551B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786172P 2013-03-14 2013-03-14
US201361906567P 2013-11-20 2013-11-20
PCT/US2014/028384 WO2014152955A1 (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
MX2015011350A true MX2015011350A (es) 2016-01-15
MX365551B MX365551B (es) 2019-06-07

Family

ID=50680161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011350A MX365551B (es) 2013-03-14 2014-03-14 Proteinas de fusion de apelina y usos de estas.

Country Status (15)

Country Link
US (3) US9353163B2 (es)
EP (1) EP2970415B1 (es)
JP (1) JP6525951B2 (es)
KR (1) KR20150127596A (es)
CN (1) CN105026423A (es)
AU (1) AU2014236451B2 (es)
BR (1) BR112015020587A2 (es)
EA (1) EA201591700A1 (es)
ES (1) ES2708957T3 (es)
HK (1) HK1220466A1 (es)
IL (1) IL240587A0 (es)
MX (1) MX365551B (es)
SG (1) SG11201506335YA (es)
WO (1) WO2014152955A1 (es)
ZA (1) ZA201505927B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236451B2 (en) 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CN105916881A (zh) 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
MX370689B (es) * 2014-06-10 2019-12-19 Amgen Inc Polipeptidos apelina.
EP3206707B1 (en) * 2014-10-13 2020-12-02 University of Maryland, Baltimore Fc-ela-32 and its use in the treatment of cardiac conditions
WO2016065042A1 (en) * 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3237435B1 (en) * 2014-12-23 2023-05-24 INSERM - Institut National de la Santé et de la Recherche Médicale Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor
US10172919B2 (en) 2014-12-29 2019-01-08 Academia Sinica Method for treating influenza A virus infection
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018053006A1 (en) * 2016-09-13 2018-03-22 Dana-Farber Cancer Institute, Inc. Methods and compositions for the positive selection of protein destabilizers
WO2018175383A1 (en) * 2017-03-22 2018-09-27 Research Corporation Technologies, Inc. Engineered stable ch2 polypeptides
JP7001285B2 (ja) * 2017-03-29 2022-01-19 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
WO2018208625A1 (en) * 2017-05-06 2018-11-15 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
WO2019040390A1 (en) * 2017-08-24 2019-02-28 Phanes Therapeutics, Inc. ANTI-APELIN ANTIBODIES AND USES THEREOF
GB201805675D0 (en) 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists
CN119613548A (zh) 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
EP4171603A4 (en) * 2020-06-25 2024-06-26 Gliknik Inc. ACE2-FC FUSION PROTEINS AND METHODS OF USE
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN117065020A (zh) * 2023-02-17 2023-11-17 山东大学 抑制aplnr表达或降低aplnr活性的物质在制备治疗瘢痕药物中的应用
WO2025213190A1 (en) 2024-04-05 2025-10-09 BioAge Labs, Inc. Methods of treating a disease or condition associated with weight gain

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU650629B2 (en) 1989-08-09 1994-06-30 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
EP1040189B1 (en) 1997-12-24 2008-01-09 Takeda Pharmaceutical Company Limited Polypeptides, their production and use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
WO2002036762A1 (fr) 2000-10-30 2002-05-10 Takeda Chemical Industries, Ltd. Procede de fabrication de peptides
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7736646B2 (en) 2003-03-12 2010-06-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US7450586B2 (en) * 2003-07-22 2008-11-11 Motorola, Inc. Network header compression arrangement
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
WO2006023893A2 (en) 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
US20090233854A1 (en) 2005-12-20 2009-09-17 Takeda Pharmaceutical Company Limited Novel application of apelin
BRPI0811637B8 (pt) * 2007-05-30 2021-05-25 Genexine Inc proteínas de fusão da imunoglobulina
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
CN102203117A (zh) 2008-11-04 2011-09-28 安科治疗公司 Apj受体化合物
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US9174428B2 (en) * 2009-08-10 2015-11-03 Corning Incorporated Roll mechanics for enabling printed electronics
KR102378465B1 (ko) 2009-11-02 2022-03-28 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP5953303B2 (ja) * 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
US8881594B2 (en) * 2011-03-06 2014-11-11 Alexander Henry Slocum Tapered spiral bellows pressure sensor
DK2683360T3 (en) * 2011-03-11 2016-05-30 Genzyme Corp PEGYLED APELIN AND APPLICATIONS THEREOF
WO2012133825A1 (ja) 2011-03-31 2012-10-04 株式会社資生堂 ホットフラッシュの抑制剤
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
CN104115290B (zh) * 2011-11-23 2017-04-05 夸克星有限责任公司 提供光的不对称传播的发光装置
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN102675470B (zh) * 2012-04-01 2015-06-17 江苏省弗泰生物科技有限公司 SCF-Fc融合蛋白
JP6426107B2 (ja) * 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
AU2014236451B2 (en) 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
CN105916881A (zh) 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途

Also Published As

Publication number Publication date
SG11201506335YA (en) 2015-09-29
JP6525951B2 (ja) 2019-06-05
KR20150127596A (ko) 2015-11-17
JP2016513733A (ja) 2016-05-16
EP2970415A1 (en) 2016-01-20
ES2708957T3 (es) 2019-04-12
US20160237130A1 (en) 2016-08-18
CN105026423A (zh) 2015-11-04
HK1220466A1 (zh) 2017-05-05
US9353163B2 (en) 2016-05-31
AU2014236451A1 (en) 2015-10-15
CA2904731A1 (en) 2014-09-25
US9751921B2 (en) 2017-09-05
ZA201505927B (en) 2017-03-29
WO2014152955A1 (en) 2014-09-25
IL240587A0 (en) 2015-09-24
EA201591700A1 (ru) 2015-12-30
EP2970415B1 (en) 2018-12-19
US20180030099A1 (en) 2018-02-01
MX365551B (es) 2019-06-07
AU2014236451B2 (en) 2018-08-09
BR112015020587A2 (pt) 2017-10-10
US20140275489A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2015011350A (es) Proteinas de fusion de apelina y usos de estas.
MX387180B (es) Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX382848B (es) Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas.
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
MY172997A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MY171407A (en) New polypeptides
ZA202001167B (en) Glucagon-like peptide 1 receptor agonists and uses thereof
PL3265478T3 (pl) Białka fuzyjne zawierające białko wiążące i polipeptyd interleukiny-15 o zmniejszonym powinowactwie wobec IL15Ralfa i ich zastosowania terapeutyczne
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
MX2013014008A (es) Anticuerpo que se aglutina a un polipeptido del transportador a1 del casete de aglutinacion a adenosin trifosfato (atp) (abca 1).
LV15035A (lv) Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem
HK1243092A1 (en) Fn14-binding proteins and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration